On November 2, 2020, the SEC filed a press release announcing that ADC Therapeutics SA (ADCT) announced that it has entered into an agreement to acquire a clinical trial that will enable it to treat multiple types of cancer.  The SEC's complaint, filed in the U.S. District Court for the Southern District of New York, alleges that ADC Therapeutics failed to meet certain of its key objectives in its clinical trial.  According to the SEC's complaint, ADC Therapeutics failed to meet certain of those objectives.  The SEC's complaint, filed in federal court in New York, alleges that ADC Therapeutics violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the SEC's complaint, ADC Therapeutics has agreed to the entry of a final judgment that permanently enjoins it from violating the antifraud provisions of Sections 17(a)(1) and (3) of the Securities Act and Section 10(b) of the Exchange Act and Rule 10b-5 thereunder. The settlement is subject to court approval.  The SEC's investigation, which is continuing, is being conducted by Jennifer Creel with assistance from Brian Cheng and Kelly Shi of the Boston Regional Office.  The litigation will be led by Jennifer Creel.  The SEC appreciates the assistance of the U.S. Attorney's Office for the Southern District of New York and the Federal Bureau of Investigation.  The SEC's Office of Investor Education and Advocacy has issued anÂ Investor AlertÂ to encourage investors to check the background of anyone selling or offering them an investment using the free and simple search tool onÂ Investor.gov.